v3.26.1
OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
$ in Millions
Jun. 24, 2026
Jul. 31, 2026
Jun. 25, 2026
Oct. 31, 2025
Jul. 31, 2025
Oct. 31, 2024
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents            
Cash and cash equivalents   $ 1,758   $ 1,789    
Restricted Cash included in other assets   2   2    
Cash, cash equivalents, restricted cash and restricted cash equivalents   1,760   1,791 $ 1,537 $ 1,332
Operating Leases            
Right-of-Use Asset   $ 187   $ 183    
Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]   Other assets   Other assets    
Operating lease liability   $ 199   $ 189    
Operating Lease Liability, Statement of Financial Position [Extensible Enumeration]   Other Accrued Liabilities, Other long-term liabilities   Other Accrued Liabilities, Other long-term liabilities    
Variable Interest Entity            
Noncontrolling Interest in Variable Interest Entity   $ 40   $ 44    
Fair Value of Financial Instruments            
Carrying Value of Senior Notes   3,928   3,330    
Senior Notes 2032            
Fair Value of Financial Instruments            
Debt Instrument, Face Amount     $ 600      
Quoted Prices in Active Markets for Identical Assets (Level 1) | Senior Notes            
Fair Value of Financial Instruments            
Fair Value of Senior Notes   $ 3,749   $ 3,191    
Biocare            
Business Combination [Abstract]            
Percentage acquired 100.00%          
Net consideration transferred $ 950